LUSPATERCEPT INCREASES HEMOGLOBIN AND REDUCES TRANSFUSION BURDEN IN PATIENTS WITH LOW OR INTERMEDIATE-1 RISK MYELODYSPLASTIC SYNDROMES (MDS): PRELIMINARY RESULTS FROM A PHASE 2 STUDY

被引：1

作者：

Platzbecker, U. ^{[1
]}

Germing, U. ^{[2
]}

Giagounidis, A. ^{[3
]}

Goetze, K. ^{[4
]}

Kiewe, P. ^{[5
]}

Mayer, K. ^{[6
]}

Ottmann, O. ^{[7
]}

Radsak, M. ^{[8
]}

Wolff, T. ^{[9
]}

Haase, D. ^{[10
]}

Hankin, M. ^{[11
]}

Wilson, D. ^{[11
]}

Zhang, X. ^{[11
]}

Laadem, A. ^{[12
]}

Sherman, M. ^{[11
]}

Attie, K. ^{[11
]}

机构：

[1] Univ Klinikum Carl Gustav Carus, Med Klin & Poliklin 1, Dresden, Germany

[2] Univ Klinikum Dusseldorf, Klin Hamatol Onkol & Klin Immunol, Dusseldorf, Germany

[3] Marien Hosp, Klin Onkol Hamatol & Palliat Med, Dusseldorf, Germany

[4] Tech Univ Munich, Med Klin & Poliklin 3, D-80290 Munich, Germany

[5] Onkol Schwerpunkt Oskar Helene Heim, Med Versorgungszentrum, Berlin, Germany

[6] Univ Klinikum Bonn, Med Klin & Poliklin 3, Bonn, Germany

[7] Klinikum JW Goethe Univ, Med Klin Hamatol Onkol 2, Frankfurt, Germany

[8] Johannes Gutenberg Univ Mainz, Med Klin 3, Univ Med Ctr, D-55122 Mainz, Germany

[9] OncoRes Lerchenfeld UG, Hamatol Intern Onkol Palliat Med, Hamburg, Germany

[10] Univ Med Gottigen, Abt Hamatol & Onkol, Gottingen, Germany

[11] Acceleron Pharma, Med Res, Cambridge, MA USA

[12] Celgene Corp, Med Res, Summit, NJ USA

来源：

LEUKEMIA RESEARCH | 2015年 / 39卷

关键词：

D O I：

10.1016/S0145-2126(15)30054-0

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S25 / S25

页数：1

共 50 条

[1] LUSPATERCEPT INCREASES HEMOGLOBIN AND REDUCES TRANSFUSION BURDEN IN PATIENTS WITH LOW OR INTERMEDIATE-1 RISK MYELODYSPLASTIC SYNDROMES (MDS): PRELIMINARY RESULTS FROM THE PHASE 2 PACE-MDS STUDY
Platzbecker, U.
Germing, U.
Giagounidis, A.
Goetze, K.
Kiewe, P.
Mayer, K.
Ottmann, O.
Radsak, M.
Wolff, T.
Haase, D.
Hankin, M.
Wilson, D.
Zhang, X.
Laadem, A.
Sherman, M.
Attie, K.
[J]. HAEMATOLOGICA, 2015, 100 : 192 - 192
[2] ACE-536 Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Preliminary Results from a Phase 2 Study
Platzbecker, Uwe
Germing, Ulrich
Giagounidis, Aristoteles
Goetze, Katharina
Kiewe, Philipp
Mayer, Karin
Ottman, Oliver
Radsak, Markus P.
Wolff, Thomas
Haase, Detlef
Hankin, Monty
Wilson, Dawn M.
Laadem, Adberrahmane
Sherman, Matthew L.
Attie, Kenneth M.
[J]. BLOOD, 2014, 124 (21)
[3] Luspatercept Treatment Leads to Long Term Increases in Hemoglobin and Reductions in Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Preliminary Results from the Phase 2 PACE-MDS Extension Study
Giagounidis, Aristoteles
Platzbecker, Uwe
Germing, Ulrich
Goetze, Katharina
Kiewe, Philipp
Mayer, Karin Tina
Ottmann, Oliver
Radsak, Markus
Wolff, Thomas
Haase, Detlef
Hankin, Monty
Wilson, Dawn
Zhang, Xiaosha
Laadem, Adberrahmane
Sherman, Matthew L.
Attie, Kenneth M.
[J]. BLOOD, 2015, 126 (23)
[4] Luspatercept Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low-Intermediate Risk Myelodysplastic Syndromes (MDS): Long-Term Results from Phase 2 PACE-MDS Study
Platzbecker, Uwe
Germing, Ulrich
Gotze, Katharina
Kiewe, Philipp
Wolff, Thomas
Mayer, Karin
Chromik, Joerg
Radsak, Markus
Donovan, Eileen
Wilson, Dawn M.
Zhang, Xiaosha
Laadem, Abderrahmane
Sherman, Matthew L.
Attie, Kenneth M.
Giagounidis, Aristoteles
[J]. BLOOD, 2016, 128 (22)
[5] LUSPATERCEPT INCREASES HEMOGLOBIN AND REDUCES TRANSFUSION BURDEN IN PATIENTS WITH LOW-INTERMEDIATE RISK MYELODYSPLASTIC SYNDROMES (MDS): LONG-TERM RESULTS FROM PHASE 2 PACE-MDS STUDY
Platzbecker, U.
Giagounidis, A.
Germing, U.
Goetze, K.
Kiewe, P.
Mayer, K.
Chromik, J.
Radsak, M.
Wolff, T.
Donovan, E.
Wilson, D.
Zhang, X.
Laadem, A.
Sherman, M.
Attie, K.
[J]. HAEMATOLOGICA, 2016, 101 : 16 - 16
[6] ACE-536 INCREASES HEMOGLOBIN LEVELS IN PATIENTS WITH LOW OR INTERMEDIATE-1 RISK MYELODYSPLASTIC SYNDROMES (MDS): PRELIMINARY RESULTS FROM A PHASE 2 STUDY
Platzbecker, U.
Germing, U.
Giagounidis, A.
Goetze, K.
Kiewe, P.
Mayer, K.
Ottmann, O.
Radsak, M.
Wolff, T.
Hankin, M.
Wilson, D.
Sherman, M.
Attie, K.
[J]. HAEMATOLOGICA, 2014, 99 : 500 - 500
[7] LUSPATERCEPT INCREASES HEMOGLOBIN AND REDUCES TRANSFUSION BURDEN IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (MDS): LONG-TERM RESULTS FROM PHASE 2 PACE-MDS STUDY
Giagounidis, A.
Germing, U.
Goetze, K.
Kiewe, P.
Wolff, T.
Mayer, K.
Chromik, J.
Radsak, M.
Wilson, D.
Zhang, X.
Laadem, A.
Sherman, M. L.
Attie, K. M.
Linde, P. G.
Platzbecker, U.
[J]. HAEMATOLOGICA, 2017, 102 : 264 - 264
[8] Biomarkers of Ineffective Erythropoiesis Predict Response to Luspatercept in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Final Results from the Phase 2 PACE-MDS Study
Platzbecker, Uwe
Germing, Ulrich
Giagounidis, Aristoteles
Goetze, Katharina
Kiewe, Philipp
Mayer, Karin Tina
Ottmann, Oliver
Radsak, Markus
Wolff, Thomas
Haase, Detlef
Hankin, Monty
Wilson, Dawn
Zhang, Xiaosha
Laadem, Abderrahmane
Sherman, Matthew L.
Attie, Kenneth M.
[J]. BLOOD, 2015, 126 (23)
[9] Daratumumab in transfusion-dependent patients with low or intermediate-1 risk myelodysplastic syndromes
Garcia-Manero, Guillermo
Diez-Campelo, Maria
Vellenga, Edo
Jacoby, Meagan A.
Merchan, Brayan
Breems, Dimitri
Cortelezzi, Agostino
Doronin, Vadim
Gomez, Valle
Beckers, Marielle
Della Porta, Matteo Giovanni
Varsos, Helen
Xiu, Liang
DeAngelis, Nikki
Nnane, Ivo
Rose, Esther
van Eygen, Koen
[J]. AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (04) : E111 - E114
[10] Diagnostic procedures and treatment of patients with Myelodysplastic Syndromes (MDS) of low and intermediate-1 risk. Results of the outpatient MDS registry
Schmitz, S.
Boettger, I
Schnell, R.
Lerchenmueller, C.
Sauer, A.
Severin, K.
Germing, U.
Steinmetz, H. T.
[J]. ONKOLOGIE, 2012, 35 : 148 - 148

← 1 2 3 4 5 →